Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Improved HIV-1 Viral Load Monitoring Capacity Using Pooled Testing With Marker-Assisted Deconvolution.

Tytuł:
Improved HIV-1 Viral Load Monitoring Capacity Using Pooled Testing With Marker-Assisted Deconvolution.
Autorzy:
Liu T; Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, RI; †Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya; Departments of ‡Statistics and Data Sciences; §Integrative Biology, University of Texas at Austin, Austin, TX; ‖Division of Infectious Diseases, the Alpert Medical School of Brown University, Providence, RI; and ¶Department of Medicine, School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya.
Hogan JW
Daniels MJ
Coetzer M
Xu Y
Bove G
DeLong AK
Ledingham L
Orido M
Diero L
Kantor R
Źródło:
Journal of acquired immune deficiency syndromes (1999) [J Acquir Immune Defic Syndr] 2017 Aug 15; Vol. 75 (5), pp. 580-587.
Typ publikacji:
Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
Język:
English
Imprint Name(s):
Original Publication: Hagerstown, MD : Lippincott Williams & Wilkins, Inc., c1999-
MeSH Terms:
Viral Load*/drug effects
HIV Infections/*virology
Algorithms ; Anti-HIV Agents/therapeutic use ; CD4 Lymphocyte Count ; Drug Resistance, Viral ; HIV Infections/drug therapy ; HIV-1/drug effects ; HIV-1/growth & development ; Health Resources ; Humans ; Kenya ; Models, Theoretical ; Reproducibility of Results
References:
Stat Appl Genet Mol Biol. 2007;6:Article7. (PMID: 17402922)
AIDS. 2007 May 31;21(9):1205-6. (PMID: 17502731)
Stat Med. 2012 Nov 30;31(27):3261-8. (PMID: 22415972)
Lancet. 2015 Jul 11;386(9989):171-218. (PMID: 26117719)
J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):e70-4. (PMID: 21124228)
Clin Infect Dis. 2009 Aug 1;49(3):454-62. (PMID: 19569972)
Trop Med Int Health. 2009 Oct;14(10):1220-5. (PMID: 19624478)
Clin Infect Dis. 2014 Feb;58(3):407-12. (PMID: 24218101)
J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):e110-9. (PMID: 26470034)
AIDS. 2012 Mar 27;26(6):768-70. (PMID: 22269974)
Scand J Infect Dis. 2014 Feb;46(2):136-40. (PMID: 24228824)
J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):134-7. (PMID: 23892241)
Biometrics. 1999 Jun;55(2):608-12. (PMID: 11318222)
AIDS. 2005 Aug 12;19(12):1323-5. (PMID: 16052089)
AIDS. 2009 Mar 27;23(6):697-700. (PMID: 19209067)
J Int AIDS Soc. 2009 Mar 04;12:3. (PMID: 19261189)
Clin Infect Dis. 2007 Jan 1;44(1):128-34. (PMID: 17143828)
Clin Infect Dis. 2016 Apr 15;62(8):1043-8. (PMID: 26743094)
Biometrics. 2007 Dec;63(4):1152-63. (PMID: 17501946)
J Clin Microbiol. 2008 May;46(5):1785-92. (PMID: 18353930)
AIDS. 2009 Oct 23;23(16):2151-8. (PMID: 19730348)
Clin Infect Dis. 2011 Jan 15;52(2):264-70. (PMID: 21288854)
J Acquir Immune Defic Syndr. 2010 Feb;53(2):194-201. (PMID: 19770802)
J Clin Microbiol. 2014 Feb;52(2):517-23. (PMID: 24478482)
Biometrics. 2012 Mar;68(1):287-96. (PMID: 21762119)
BMC Med. 2014 Sep 08;12:173. (PMID: 25197773)
J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):220-4. (PMID: 24047971)
J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):256-61. (PMID: 26135327)
PLoS Med. 2008 May 20;5(5):e109. (PMID: 18494555)
J Am Stat Assoc. 2010 Sep 1;105(491):942-955. (PMID: 21113353)
Curr HIV/AIDS Rep. 2006 Jul;3(2):79-85. (PMID: 16608664)
J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):e87-93. (PMID: 23542638)
J Am Stat Assoc. 2013 Jan 1;108(504):1173-1188. (PMID: 24672142)
AIDS. 2000 Dec 1;14(17):2751-7. (PMID: 11125894)
Clin Infect Dis. 2013 May;56(9):1344-6. (PMID: 23315314)
AIDS. 2008 Oct 1;22(15):1971-7. (PMID: 18784460)
J Int AIDS Soc. 2016 May 25;19(1):20798. (PMID: 27231099)
Grant Information:
P2C HD041020 United States HD NICHD NIH HHS; P30 AI042853 United States AI NIAID NIH HHS; R01 AI108441 United States AI NIAID NIH HHS
Substance Nomenclature:
0 (Anti-HIV Agents)
Entry Date(s):
Date Created: 20170511 Date Completed: 20171018 Latest Revision: 20200930
Update Code:
20240104
PubMed Central ID:
PMC5503773
DOI:
10.1097/QAI.0000000000001424
PMID:
28489730
Czasopismo naukowe
Objective: Improve pooled viral load (VL) testing to increase HIV treatment monitoring capacity, particularly relevant for resource-limited settings.
Design: We developed marker-assisted mini-pooling with algorithm (mMPA), a new VL pooling deconvolution strategy that uses information from low-cost, routinely collected clinical markers to determine an efficient order of sequential individual VL testing and dictates when the sequential testing can be stopped.
Methods: We simulated the use of pooled testing to ascertain virological failure status on 918 participants from 3 studies conducted at the Academic Model Providing Access to Healthcare in Eldoret, Kenya, and estimated the number of assays needed when using mMPA and other pooling methods. We also evaluated the impact of practical factors, such as specific markers used, prevalence of virological failure, pool size, VL measurement error, and assay detection cutoffs on mMPA, other pooling methods, and single testing.
Results: Using CD4 count as a marker to assist deconvolution, mMPA significantly reduces the number of VL assays by 52% [confidence interval (CI): 48% to 57%], 40% (CI: 38% to 42%), and 19% (CI: 15% to 22%) compared with individual testing, simple mini-pooling, and mini-pooling with algorithm, respectively. mMPA has higher sensitivity and negative/positive predictive values than mini-pooling with algorithm, and comparable high specificity. Further improvement is achieved with additional clinical markers, such as age and time on therapy, with or without CD4 values. mMPA performance depends on prevalence of virological failure and pool size but is insensitive to VL measurement error and VL assay detection cutoffs.
Conclusions: mMPA can substantially increase the capacity of VL monitoring.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies